SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 167 filers reported holding SAGE THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $355,000 | -86.9% | 4,920 | -74.6% | 0.02% | -87.4% |
| Q3 2019 | $2,716,000 | -12.6% | 19,356 | +14.0% | 0.19% | -10.3% |
| Q2 2019 | $3,109,000 | +14.3% | 16,986 | -0.7% | 0.21% | +3.4% |
| Q1 2019 | $2,721,000 | +2.0% | 17,105 | +5.6% | 0.21% | +7.9% |
| Q4 2017 | $2,667,000 | -50.3% | 16,200 | -81.2% | 0.19% | -52.7% |
| Q3 2017 | $5,364,000 | -29.7% | 86,100 | -10.1% | 0.40% | -25.7% |
| Q2 2017 | $7,629,000 | -12.7% | 95,755 | -22.2% | 0.54% | -7.2% |
| Q1 2017 | $8,743,000 | +52.0% | 123,055 | +9.2% | 0.59% | +23.9% |
| Q4 2016 | $5,753,000 | +252.9% | 112,655 | +218.2% | 0.47% | +333.9% |
| Q3 2016 | $1,630,000 | +4.1% | 35,400 | -31.9% | 0.11% | +13.5% |
| Q2 2016 | $1,566,000 | -8.4% | 52,000 | -2.4% | 0.10% | -11.9% |
| Q1 2016 | $1,709,000 | -48.7% | 53,300 | -6.7% | 0.11% | -45.2% |
| Q4 2015 | $3,329,000 | +2.3% | 57,100 | -25.7% | 0.20% | +5.3% |
| Q3 2015 | $3,253,000 | +18.8% | 76,900 | +105.1% | 0.19% | +40.0% |
| Q2 2015 | $2,738,000 | – | 37,500 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |